Avitide, Inc., the leader in the discovery, manufacture, and supply of novel affinity purification solutions for the biopharmaceutical industry, closed its Series D financing. Mithril Capital Management, LLC led the financing round.

Avitide rapidly and reliably develops high-performance affinity purification solutions for the manufacture of life-saving therapeutics, including enzymes, novel scaffolds, multi-specific antibodies, gene therapies, and vaccines. By solving complex protein purification challenges that currently require multiple chromatography steps, Avitide enables its partners to achieve faster bioprocess development timelines, reduced program risk, improved drug performance, more predictable commercial scalability, and lower cost of manufacturing.

Read More